Anti-tumor compound and preparation method and use thereof
The present application relates to an anti-tumor compound and a preparation method and use thereof, and in particular to a compound or a tautomer, a mesomer, a racemate, an enantiomer or a diastereoisomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, and a preparation method and use thereof.
1. A compound of general formula (II-E x ) or a tautomer, a mesomer, a racemate, an enantiomer or a diastereoisomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof,
wherein, X 1 is saturated C, and X 1 is substituted with R n ;
ring A is a four-membered saturated carbocyclyl;
p is 1, and L 2 is not R n ;
L 2 is —R 2 -L 3 -;
L 3 is —(C(R 3a )(R 3b )) m —, and m is selected from the group consisting of integers from 0 to 2, wherein when L 3 comprises a methylene unit, 0 or 1 methylene unit of L 3 may be replaced by —C(O)—;
R 2 is —O—;
L 1 is —(C(R 5a )(R 5b )) n —, and n is selected from 0 or 1;
wherein when L 1 comprises a methylene unit, 0 or 1 methylene unit of L 1 may be replaced by —C(O)—;
wherein each R 3a , each R 3b , each R 5a , each R 5b and each R n may each independently be hydrogen, halogen, or a C 1-6 aliphatic group which may be optionally substituted with R n ;
wherein each R may independently be hydrogen or halogen.
2. The compound or the tautomer, the mesomer, the racemate, the enantiomer or the diastereoisomer thereof, or the mixture thereof, or the pharmaceutically acceptable salt thereof according to claim 1 , wherein m is 0, and L 3 is a covalent bond.
3. The compound or the tautomer, the mesomer, the racemate, the enantiomer or the diastereoisomer thereof, or the mixture thereof, or the pharmaceutically acceptable salt thereof according to claim 1 , wherein m is 1, and L 3 is —C(R 3a )(R 3b )—.
4. The compound or the tautomer, the mesomer, the racemate, the enantiomer or the diastereoisomer thereof, or the mixture thereof, or the pharmaceutically acceptable salt thereof according to claim 1 , wherein m is 2, and L 3 is —(C(R 3a )(R 3b )) 2 —.
5. The compound or the tautomer, the mesomer, the racemate, the enantiomer or the diastereoisomer thereof, or the mixture thereof, or the pharmaceutically acceptable salt thereof according to claim 1 , wherein n is 1, and L 1 is —C(R 5a )(R 5b )—.
6. The compound or the tautomer, the mesomer, the racemate, the enantiomer or the diastereoisomer thereof, or the mixture thereof, or the pharmaceutically acceptable salt thereof according to claim 1 , wherein 1 methylene unit of L 1 is replaced by —C(O)—.
7. The compound or the tautomer, the mesomer, the racemate, the enantiomer or the diastereoisomer thereof, or the mixture thereof, or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 3a and R 3b are each independently hydrogen.
8. The compound or the tautomer, the mesomer, the racemate, the enantiomer or the diastereoisomer thereof, or the mixture thereof, or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 5a and R 5b are each independently hydrogen.
9. The compound or the tautomer, the mesomer, the racemate, the enantiomer or the diastereoisomer thereof, or the mixture thereof, or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R n is hydrogen.
10. The compound or the tautomer, the mesomer, the racemate, the enantiomer or the diastereoisomer thereof, or the mixture thereof, or the pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is selected from the following structures:
11. A compound of general formula (II-F x ) or a tautomer, a mesomer, a racemate, an enantiomer or a diastereoisomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof,
wherein, L x is L ax -L b -L c -;
L ax - is
-L b - is:
-L c - is
wherein R L1 and R L2 are each independently selected from the group consisting of: hydrogen, halogen, —OH and a C 1-6 aliphatic group;
X 1 is saturated C, and X 1 is substituted with R n ;
ring A is a four-membered saturated carbocyclyl;
p is 1, and L 2 is not R n ;
L 2 is —R 2 -L 3 -;
L 3 is —(C(R 3a )(R 3b )) m —, and m is selected from the group consisting of integers from 0 to 2, wherein when L 3 comprises a methylene unit, 0 or 1 methylene unit of L 3 may be replaced by —C(O)—;
R 2 is —O—;
L 1 is —(C(R 5a )(R 5b )) n —, and n is selected from 0 or 1;
wherein when L 1 comprises a methylene unit, 0 or 1 methylene unit of L 1 may be replaced by —C(O)—;
wherein each R 3a , each R 3b , each R 5a , each R 5b and each R n may each independently be hydrogen, halogen, or a C 1-6 aliphatic group which may be optionally substituted with R;
wherein each R may independently be hydrogen or halogen.
12. The compound or the tautomer, the mesomer, the racemate, the enantiomer or the diastereoisomer thereof, or the mixture thereof, or the pharmaceutically acceptable salt thereof according to claim 11 , wherein L ax -L b -L c - is:
13. The compound or the tautomer, the mesomer, the racemate, the enantiomer or the diastereoisomer thereof, or the mixture thereof, or the pharmaceutically acceptable salt thereof according to claim 11 , wherein
X 1 is saturated C, and X 1 is substituted with R n ;
ring A is a four-membered saturated carbocyclyl;
p is 1, and L 2 is not R n ;
L 2 is —R 2 -L 3 -;
L 3 is —(C(R 3a )(R 3b )) m —, and m is 0, 1 or 2;
R 2 is —O—;
L 1 is —C(O)—;
wherein each R 3a , each R 3b , and each R n may each independently be hydrogen, halogen, or a C 1-6 aliphatic group which may be optionally substituted with R;
wherein each R may independently be hydrogen or halogen.
14. The compound or the tautomer, the mesomer, the racemate, the enantiomer or the diastereoisomer thereof, or the mixture thereof, or the pharmaceutically acceptable salt thereof according to claim 11 , wherein the compound is selected from the following structures:
15. A pharmaceutical composition, comprising the ligand-drug conjugate or the tautomer, the mesomer, the racemate, the enantiomer or the diastereoisomer thereof, or the mixture thereof, or the pharmaceutically acceptable salt thereof according to claim 1 , and a pharmaceutically acceptable carrier.
16. A method for treating a tumor, comprising administering to a subject in need with the compound or the tautomer, the mesomer, the racemate, the enantiomer or the diastereoisomer thereof, or the mixture thereof, or the pharmaceutically acceptable salt thereof according to claim 1 , and/or a pharmaceutical composition that may comprise the same, wherein the tumor is selected from the group consisting of: lung cancer, kidney cancer, urinary tract carcinoma, colorectal cancer, prostatic cancer, glioblastoma multiforme, ovarian cancer, pancreatic cancer, breast cancer, melanoma, liver cancer, bladder cancer, stomach cancer and esophageal cancer.